HIM
RIGL icon

Hillsdale Investment Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Hillsdale Investment Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-282,584
Closed -$12.1M – 754
2025
Q4 		$12.1M Sell
282,584
-1,810
-0.6% -$68.2K 0.33% 51
2025
Q3 		$8.06M Buy
284,394
+22,330
+9% +$668K 0.24% 77
2025
Q2 		$4.91M Buy
262,064
+69,900
+36% +$1.33M 0.18% 172
2025
Q1 		$3.46M Buy
192,164
+22,064
+13% +$448K 0.18% 155
2024
Q4 		$2.86M Buy
170,100
+151,500
+815% +$2.91M 0.14% 187
2024
Q3 		$301K Buy
+18,600
New +$219K 0.02% 366
2016
Q4 		– Sell
-2,540
Closed -$93K – 537
2016
Q3 		$93K Buy
+2,540
New +$72.8K 0.02% 307
2015
Q2 		– Sell
-1,180
Closed -$42K – 555
2015
Q1 		$42K Buy
+1,180
New +$32.4K 0.01% 445

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hillsdale Investment Management's RIGL Position: Q1 2026 in Review

Hillsdale Investment Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 282,584 shares — an estimated $12.1M sold.

Hillsdale Investment Management first reported a position in RIGL in Q1 2015 and held it in 8 quarters. The position peaked at $12.1M in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Hillsdale Investment Management reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Hillsdale Investment Management sold 282,584 Rigel Pharmaceuticals shares in Q1 2026, an estimated $12.1M.
  • Hillsdale Investment Management first reported a position in Rigel Pharmaceuticals in Q1 2015 and held it in 8 quarters.
  • Hillsdale Investment Management's Rigel Pharmaceuticals position peaked at $12.1M in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.